Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$16.79
+1.4%
$15.70
$9.60
$19.09
$2.25B1.471.03 million shs632,847 shs
Organon & Co. stock logo
OGN
Organon & Co.
$9.40
+2.3%
$9.61
$8.01
$22.67
$2.45B0.64.81 million shs4.58 million shs
Organogenesis stock logo
ORGO
Organogenesis
$5.15
+0.6%
$4.47
$2.45
$6.71
$653.32M1.75651,073 shs314,198 shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$58.58
+0.7%
$45.57
$25.82
$58.95
$2.47B0.81663,854 shs374,275 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%-1.29%-2.21%+27.78%+24.55%
Organon & Co. stock logo
OGN
Organon & Co.
0.00%-0.27%-3.09%+2.12%-58.19%
Organogenesis stock logo
ORGO
Organogenesis
0.00%+5.32%+11.47%+85.92%+75.77%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.00%+2.32%+50.90%+36.42%+120.39%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
2.6268 of 5 stars
3.51.00.00.03.52.50.6
Organon & Co. stock logo
OGN
Organon & Co.
4.7523 of 5 stars
3.32.01.73.73.01.73.1
Organogenesis stock logo
ORGO
Organogenesis
4.232 of 5 stars
3.31.00.04.33.04.20.6
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
1.6939 of 5 stars
2.41.00.00.03.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
3.00
Buy$31.5087.61% Upside
Organon & Co. stock logo
OGN
Organon & Co.
2.50
Moderate Buy$18.0091.59% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$7.5045.63% Upside
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2.83
Moderate Buy$66.6713.80% Upside

Current Analyst Ratings Breakdown

Latest ORGO, OGN, TARS, and CNTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/29/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$40.00
8/12/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
8/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$7.00 ➝ $9.00
7/30/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
7/21/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
6/2/2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$6.85M328.23N/AN/A$3.05 per share5.50
Organon & Co. stock logo
OGN
Organon & Co.
$6.40B0.38$4.92 per share1.91$1.83 per share5.13
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.36$0.21 per share24.68$2.09 per share2.46
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$182.95M13.52N/AN/A$5.87 per share9.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$235.76M-$1.79N/AN/AN/AN/A-40.39%-29.87%11/11/2025 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$864M$2.693.492.510.8611.15%163.88%6.99%10/30/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/11/2025 (Estimated)
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$115.55M-$2.33N/AN/AN/A-31.13%-32.36%-21.04%11/12/2025 (Estimated)

Latest ORGO, OGN, TARS, and CNTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.35-$0.38-$0.03-$0.38$0.63 millionN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
8/6/2025Q2 2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.33-$0.48-$0.15-$0.48$95.81 million$102.66 million
8/5/2025Q2 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.85%N/A2.97%N/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A

Latest ORGO, OGN, TARS, and CNTA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/5/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.9%8/15/20258/15/20259/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.32
10.11
10.12
Organon & Co. stock logo
OGN
Organon & Co.
11.98
1.65
1.13
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.22
5.26
5.21

Institutional Ownership

CompanyInstitutional Ownership
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
82.01%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%

Insider Ownership

CompanyInsider Ownership
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
7.09%
Organon & Co. stock logo
OGN
Organon & Co.
1.40%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
8.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
200133.91 million124.42 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
4,000259.97 million256.33 millionNot Optionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5042.21 million38.43 millionOptionable

Recent News About These Companies

Tarsus to Participate in Upcoming Investor Conferences
Biotech - Genetic Graphic
3 Biotech Catalysts Present Major Opportunity (TARS)
...
Brokers Offer Predictions for TARS Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$16.79 +0.23 (+1.39%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$16.78 0.00 (-0.03%)
As of 08/29/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$9.40 +0.22 (+2.34%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$9.43 +0.03 (+0.32%)
As of 08/29/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$5.15 +0.03 (+0.59%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$5.14 -0.01 (-0.10%)
As of 08/29/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$58.58 +0.42 (+0.72%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$58.58 +0.01 (+0.01%)
As of 08/29/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.